Aurobindo Reduces Losses Following Three Us Fda Observations

Top Stories

Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

Stock chart

Aurobindo reduces losses following three US FDA observations

ri-calendar-2-lineJul 24, 2023

By: BlinkX Research Team

FbkFbkTwitterTelegram

After the business got three observations from the US Food and Drug Administration (USFDA), Aurobindo Pharma shares recovered their initial losses and fluctuated somewhat.

Following an examination of Aurobindo Pharma's Unit III, a formulation manufacturing plant located in Bachupally Village in Telangana's Medchal Malkajgiri district, from July 14 to 21, the US FDA issued the Form 483 with three observations.

The company stated in a statement, "The observations are procedural in nature and we will respond to the USFDA within the stipulated timelines and work closely with USFDA to close the observations at the earliest." 

Additionally, from May 15 to 19, the USFDA performed an examination at the business' Unit XIV at Jawaharlal Nehru Pharma City in the Anakapalli area of Andhra Pradesh. The facility was classified as having suggested voluntary action (VAI) in the establishment inspection report, the business reported on July 17. 

Sevelamer Hydrochloride Tablets 400mg and 800mg, which are intended to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Renagel Tablets, 400mg and 800mg, of Genzyme Corporation, were given their final approval to be manufactured and marketed by Aurobindo Pharma's wholly owned subsidiary APL Healthcare on July 12.

Source: Media Reports

Related News

News Thumbnail
Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

News Thumbnail
Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

News Thumbnail
Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

News Thumbnail
Company

NBCC Arm Gets Two Construction Projects Worth Rs 443.61 Cr

4 mins read. August 2, 2024 at 12:33 PM

Related Blogs

Stock chartDemat Account

Biggest Winners and Losers in MSCI: Key Movers in Global Indices 2025

0 people read

3 mins read . Aug 20, 2025

Stock chartMutual Fund

What MF Big Boys Bought and Sold – Top Mutual Fund Stock Activity in 2025

0 people read

8 mins read . Aug 18, 2025

Download app

Access BlinkX
everywhere
across device

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions